The History of MCS

MCS's clinical history begins with Dr. Theron Randolph, a Chicago allergist-immunologist in the late 1940s–50s. He observed what standard allergy medicine couldn't explain: patients with multi-system symptoms from low-level chemical exposures, at doses far below known toxic levels.

These patients had negative standard allergy tests. Their symptoms did not fit the IgE-mediated allergy model that dominated the field. But their reactions were reproducible, consistent, and debilitating. Randolph described what he was observing as “ecologic illness” — a new category of disease related to the individual’s ecological environment rather than conventional allergen sensitization.

Randolph’s 1954 paper in the Annals of Allergy describing patterns of chemical susceptibility in patients was among the first clinical descriptions of what would later be called MCS. His 1962 book Human Ecology and Susceptibility to the Chemical Environment — written for physicians — attempted to systematize what he was observing clinically. It received little academic attention and considerable skepticism.

Today's chemical environment is fundamentally different from the one humans evolved in — a quantifiable fact, not a value judgment. That scale of change is essential context for MCS's history.

Randolph co-founded the Society for Clinical Ecology in 1965 (now the American Academy of Environmental Medicine) as a professional home for physicians treating environmental illness. Its protocols — including controlled environmental units — shaped later research design.

By the mid-1990s, two fundamentally opposed medical positions on MCS had crystallized, and they remain in tension today:

The psychological school has faced significant scientific challenge from brain imaging studies, receptor research, capsaicin challenge data, and longitudinal studies. The 2023 Molot, Sears & Anisman review in Neuroscience & Biobehavioral Reviews represented a decisive turn in the scientific literature — establishing TRP receptor sensitization as the established biological mechanism and directly addressing the inadequacy of psychological explanations.

In January 2024, a formal letter in the Journal of Allergy and Clinical Immunology: In Practice — signed by practising clinicians and researchers — warned that classifying MCS as a phobia constitutes “a dangerous pathway to iatrogenesis” and that graded chemical exposure therapy “goes against the basic principle of MCS treatment and may cause serious short-term and long-term setbacks.”

The tobacco industry’s documented strategy of funding research to create scientific doubt about the health effects of smoking established a template that has been applied in other industries. In the case of MCS, several documented events are part of the public record:

Canada has been among the most proactive: the Canadian Human Rights Commission recognized MCS as a disability in 2007.

The federal Policy on Environmental Sensitivities (2007, updated 2019) set scent-free guidelines for public spaces — cited internationally as a model.

'Scientific consensus' is often claimed prematurely. But by 2023, the MCS evidence base had reached a point where leading researchers described it in terms that would have been unpublishable a decade earlier.

The landmark 2023 review by Molot, Sears & Anisman in Neuroscience & Biobehavioral Reviews synthesized decades of research and concluded that:

This language — “no longer scientifically defensible” as a description of the psychological position — represents a significant shift in how the field is characterizing the state of evidence. It does not resolve all open questions about mechanisms, subgroups, or optimal treatment. But it marks the end of the period in which dismissing MCS as psychological could claim scientific credibility.

The 1999 Consensus Criteria remain the most widely used clinical case definition. The biological mechanisms that explain why patients meeting those criteria have the symptoms they do are now substantially clearer than they were when the criteria were written. The science has not caught up to the clinical reality — it has finally begun to.

The biological understanding of MCS that has accumulated in the past decade opens research directions that were not available when the condition was classified primarily as psychological. Several active areas are producing results that may eventually change treatment options:

The history of MCS is the history of a condition that existed decades before medicine was willing to recognize it. The patients who have lived with it for that entire period deserve acknowledgment that the scientific record has been catching up to their experience — not the other way around.